What is Zacks Research's Forecast for ESPR FY2025 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at Zacks Research lifted their FY2025 EPS estimates for Esperion Therapeutics in a research note issued to investors on Thursday, July 10th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings of ($0.42) per share for the year, up from their previous estimate of ($0.43). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics' Q1 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.24) EPS, Q1 2027 earnings at ($0.19) EPS and Q2 2027 earnings at $0.05 EPS.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). Esperion Therapeutics had a negative net margin of 59.03% and a negative return on equity of 0.91%. The company had revenue of $65.00 million for the quarter, compared to the consensus estimate of $54.97 million.

Several other equities research analysts have also recently commented on ESPR. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, June 17th. Needham & Company LLC dropped their price target on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, The Goldman Sachs Group dropped their price target on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.

Esperion Therapeutics Trading Down 4.0%

Shares of Esperion Therapeutics stock opened at $1.19 on Monday. The company's 50-day moving average price is $1.01 and its two-hundred day moving average price is $1.42. Esperion Therapeutics has a 52 week low of $0.69 and a 52 week high of $3.94. The stock has a market cap of $235.86 million, a PE ratio of -1.49 and a beta of 0.70.

Institutional Investors Weigh In On Esperion Therapeutics

Several large investors have recently made changes to their positions in ESPR. Sivia Capital Partners LLC bought a new stake in shares of Esperion Therapeutics in the 2nd quarter valued at approximately $25,000. Meridian Wealth Management LLC bought a new stake in shares of Esperion Therapeutics in the 1st quarter valued at approximately $29,000. Cibc World Markets Corp bought a new stake in shares of Esperion Therapeutics in the 4th quarter valued at approximately $39,000. Synergy Asset Management LLC lifted its holdings in Esperion Therapeutics by 3,496.3% in the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 30,138 shares during the last quarter. Finally, Private Advisor Group LLC lifted its holdings in Esperion Therapeutics by 33.2% in the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.